Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Modern Endoscopic Imaging in Diagnosis and Surveillance of Inflammatory Bowel Disease Patients

    Research output: Contribution to journalReviewResearchpeer-review

  3. The Effect of a Synthetic Heparan Sulfate on the Healing of Colonic Anastomoses

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exercise training and the progression of chronic renal failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pancreatic function in Crohn's disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Svein Oskar Frigstad
  • Anne Haaber
  • Antal Bajor
  • Jan Fallingborg
  • Per Hammarlund
  • Ole K Bonderup
  • Håkan Blom
  • Terje Rannem
  • Per M Hellström
View graph of relations

Background: Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract.

Objective: The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside.

Methods: A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year.

Results: Out of 282 patients, 82 had Crohn's disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients.

Conclusion: Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial is registered with NCT01900197.

Original languageEnglish
JournalGastroenterology Research and Practice
Volume2017
Pages (from-to)4585164
ISSN1687-6121
DOIs
Publication statusPublished - 2017

    Research areas

  • Journal Article

ID: 52743778